News for MYGN Stock

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing Myriad Genetics Announces Inducement Awards Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Myriad Genetics Announces Senior Leadership Transition Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio Myriad Genetics Included in Forbes America’s Best Employers 2025 List Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference Myriad Genetics Introduces Online Prenatal Genetic Testing Resource Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference Myriad Genetics to Host Investor Event on October 9, 2024 Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Myriad Genetics Earns 2024 Great Place To Work® Certification™ Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers Myriad Genetics to Participate in Stephens Annual Investment Conference Myriad Genetics Announces Pricing of Upsized Offering of Common Stock Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance Myriad Genetics Appoints Sam Raha as Chief Operating Officer Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023 QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials Myriad Genetics Issues 2022 Environmental, Social and Governance Report Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk Myriad Genetics to Host Investor Day on September 19, 2023 Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris® Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023 Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment Myriad Genetics Announces New $90 Million Asset-Based Credit Facility Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform Myriad Genetics to Participate in Goldman Sachs Healthcare Conference Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023 Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer Myriad Genetics Earns 2023 Great Place to Work Certification™ Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range Myriad Genetics to Participate in BofA Securities Healthcare Conference Myriad Genetics to Release First Quarter Financial Results on May 3, 2023 Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023 Myriad Genetics to Participate in Upcoming Healthcare Conferences Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test Myriad Genetics Reports Third Quarter Financial Results Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022 Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe Myriad Genetics Reports Second Quarter Financial Results Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022 Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022 Myriad Genetics Issues Inaugural Environmental, Social and Governance Report Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022 Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022 2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022 Myriad Genetics to Present at Two Upcoming Healthcare Conferences Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021 Myriad Genetics Names Pamela Wong as Chief Legal Officer Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021 New research reveals most Americans can’t identify the symptoms of depression Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021 Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels Myriad Genetics Forms Strategic Partnership with Illumina in Oncology Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations IPM Launches Innovative Program for Rheumatoid Arthritis Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020 German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests Myriad Genetics Expands Board of Directors with New Member American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020 Myriad Launches New GeneSight® Psychotropic Patient Collection Kit Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra® Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction